Genelux Corporation Common Stock is a biopharmaceutical company that specializes in the development and commercialization of innovative oncolytic immunotherapies. They aim to improve cancer treatment by using their proprietary technology to selectively target cancer cells while sparing healthy tissues. With a strong pipeline and ongoing clinical trials, Genelux is poised to make a significant impact in the field of cancer immunotherapy.
Notification